Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Giacomo Moretti has a total of 80 co-authors. Here are the top co-authors by number of shared publications:

  • Andrea Urbani

    Clinical Chemistry, Biochemistry and Molecular Biology Operations (UOC), Fondazione Policlinico Universitario A. Gemelli IRCCS , Rome

    5 shared publications
  • Andrea Urbani

    Unit of Chemistry, Biochemistry and Molecular Biology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 1, 00168 Rome, Italy

    5 shared publications
  • Silvia Baroni

    Department of laboratory and infectious disease, Università Cattolica del Sacro Cuore, Rome, Italy

    4 shared publications
  • Silvia Baroni

    Department of Basic Biotechnological Sciences, Intensive Care and Perioperative Clinics , Catholic University of Sacred Heart , Rome , Italy

    4 shared publications
  • Maria Elisabetta Onori

    Departmental Unit of Molecular and Genomic Diagnostics, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy

    3 shared publications
  • Angelo Minucci

    Molecular Diagnostics and Genomics Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

    2 shared publications

Latest Publications

  • Open Access

    Comprehensive Evaluation of a Point-of-Care Testing Platform for Decentralized Primary Healthcare: Ensuring Analytical Quality Through Central Laboratory Oversight

    by Giacomo Moretti, Francesca Danila Alcaro, Luigi Colacicco, Andrea Urbani

    Background/Objectives: Point-of-care testing (POCT) is increasingly adopted in primary healthcare to facilitate rapid screening and monitoring of chronic conditions. Ensuring that its analytical quality is comparable to central laboratory testing is crucial for safe and effective implementation. This study aims to rigorously evaluate the analytical performance of the Allegro POCT system against established central laboratory reference methods to determine its suitability for decentralized healthcare settings. Methods: We assessed the correlation, concordance, and bias of glycated hemoglobin (HbA1c), glucose (GLUC), total cholesterol (CHOL), high-density lipoprotein cholesterol (HDL), triglycerides (TRIG), creatinine (CREA), and C-reactive protein (CRP). Using a cohort of 100 residual patient samples, measurements from the Allegro POCT system were compared against reference methods on the Atellica CH 930 Analyzer and TOSOH G8 system. The statistical analysis was performed using Deming regression, Bland–Altman plots, and Pearson correlation. Results: HbA1c and GLUC demonstrated strong linearity and correlation (Pearson’s r = 0.9863 and r = 0.9994, respectively). A slight positive bias was noted for HbA1c at higher concentrations. In the lipid panel, CHOL showed a significant positive bias (mean bias +14.2 mg/dL), while TRIG exhibited a substantial negative bias (mean bias −37.0 mg/dL) and wide limits of agreement. HDL and CREA showed good linearity but only moderate agreement. CRP demonstrated excellent concordance with the reference method (Pearson’s r = 0.9955) and minimal bias. Conclusions: The Allegro system exhibits acceptable analytical performance for GLUC and CRP, rendering it suitable for decentralized use. HbA1c and CREA performance is adequate, though caution is advised due to observed biases. However, the significant biases for CHOL and TRIG underscore the indispensable role of central laboratory oversight in any POCT program. Rigorous initial validation and continuous quality monitoring under a robust governance framework are essential to ensure the reliability and clinical utility of POCT.

  • Point-of-Care Testing Glucometer in Rapid Assessment Settings: Comparison of 2 Network-Capable Devices in a Referral Hospital

    by Giacomo Moretti, Giorgia Degni, Camilla Lamiano, Eugenia Tulli, Andrea Urbani

    Background: Point-of-care testing (POCT) glucose meters are essential for rapid glucose monitoring. This study aimed to evaluate the analytical performance of 2 novel network-capable POCT glucometers, CobasPulse (Roche Diagnostic) and StatStrip (Nova Biomedical), in comparison to the Atellica CH 930 Analyzer (Siemens Healthcare), a central laboratory clinical chemistry analyzer, as a reference method. Methods: A cohort of 150 patients’ venous whole blood samples were analyzed. Method comparison was performed using Passing–Bablok regression and Bland–Altman plots. Precision studies were conducted using commercial controls, with assessment of within-run and between-run imprecision by experienced laboratory technicians. Performance was assessed against FDA 2020 benchmarks. Results: Passing–Bablok regression showed accurate overlap for both POCT devices. CobasPulse exhibited a bias of −0.17 mmol/L and Pearson r of 0.982, while StatStrip showed a bias of −0.35 mmol/L and Pearson r of 0.959. Within-run CV for Cobas Pulse (3.3 mmol/L control) was 2.4%, and for StatStrip (3.44 mmol/L control) was 5.2%. Between-run CVs were 2.1% for Cobas Pulse and 3.2% for StatStrip at comparable glucose concentrations. Conclusions: Both CobasPulse and StatStrip demonstrated acceptable concordance with the Atellica CH 930 Analyzer. While Cobas Pulse showed slightly better agreement and precision, both devices are suitable for glucose measurements in healthcare settings, providing reliable results and reduced turnaround time, supporting timely clinical decisions for rapid glycemic assessment.


  • Open Access

    COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer

    by Emanuele Vita, Federico Monaca, Luca Mastrantoni, Geny Piro, Giacomo Moretti, Ileana Sparagna, Alessio Stefani, Antonio Vitale, Giovanni Trovato, Mariantonietta Di Salvatore, et al.

    Background: As COVID-19 has become an epidemic, we conducted an open-label study aimed to identify immunogenicity and reactogenicity of boosters of the BNT162b2 vaccine in a real-world cohort of long-survivor metastatic lung cancer patients (LS-mLC pts). Methods and Analysis: According to the timing of the booster dose (BD) and SARS-CoV-2 infection (Cov-I) during anticancer treatment (ACT), between October 2021 and February 2022, we prospectively enrolled 166 cancer patients into five parallel cohorts. The primary endpoints were seroprevalence of IgG Anti-spike-RBD (anti-S IgG) at two pre-defined timepoints (T1: +30–90 days after BD; T2: +6 months +/− 4 weeks after BD). As an exploratory endpoint, we compared the median pre-vaccination value of four cytokines (IL-6, IL-2R, TNF-α, IL-10) with post-BD values in immunotherapy-treated pts (IO-pts). Results: The anti-S IgG seropositivity rate was 100% at T1 and 98.8% at T2. After 6 months, hybrid immunisation was associated with a higher median anti-S IgG titre compared to vaccine-alone-induced seroconversion (p < 0.0001). In uninfected pts, the median anti-S IgG titre was significantly lower in IO-pts compared to non-IO-pts (p = 0.02); no difference was found when comparing myelosuppressive or not ACT. Among the 68 IO-pts, 5 pts (7.3%) showed a significant increase (≥1.5 fold) of at least two cytokines in post-BD samples, without reporting ir-AEs. Conclusions: Boosters of the COVID-19 mRNA vaccine were effective and safe. In IO-pts without recent Cov-I, additional BDs should be considered to prolong serological immunity.

  • Relation between high-sensitivity troponin I serum levels and myocardial ischemia in patients with suspected chronic coronary syndrome: The RESET-MI study

    by Antonio De Vita, Isabella Bruno, Silvia Baroni, Giacomo Moretti, Federica Tempestini, Alessandro Telesca, Saverio Tremamunno, Tamara Felici, Alfonso Verrillo, Valeria Tempesta, et al.


  • Open Access

    Sinonasal Biomarkers Defining Type 2-High and Type 2-Low Inflammation in Chronic Rhinosinusitis with Nasal Polyps

    by Eugenio De Corso, Silvia Baroni, Stefano Settimi, Maria Elisabetta Onori, Rodolfo Francesco Mastrapasqua, Eliana Troiani, Giacomo Moretti, Donatella Lucchetti, Marco Corbò, Claudio Montuori, et al.

    The complex pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP) generates a spectrum of phenotypes with a wide variety of inflammatory states. We enrolled 44 very-likely-to-be type 2 CRSwNP patients in order to evaluate the load of inflammation and to analyze human interleukins in nasal secretion. Clinical data were collected to evaluate the severity of the disease. High levels of IL-5, IL-4, IL-6, and IL-33 were detected in all type 2 CRSwNP patients. By analyzing type 2 cytokine profiles and local eosinophil count, we identified two coherent clusters: the first was characterized by high levels of IL-4, IL-5, IL-6, and a high-grade eosinophil count (type 2-high); the second had lower levels of cytokines and poor or absent eosinophilic inflammation (type-2 low). IL-5 levels were significantly higher within the type 2 cytokine and it was the most reliable biomarker for differentiating the two clusters. In type 2-high inflammatory profile clinical scores, the mean number of previous surgeries and need for systemic corticosteroids were significantly higher compared to type 2-low. Our research demonstrated the potential role of type 2 biomarkers, and in particular, of IL-5 in identifying patients with a more severe phenotype based on a high inflammatory load.


  • Open Access

    Genetics and Sport Injuries: New Perspectives for Athletic Excellence in an Italian Court of Rugby Union Players

    by Maria Elisabetta Onori, Massimo Pasqualetti, Giacomo Moretti, Giulia Canu, Giulio De Paolis, Silvia Baroni, Angelo Minucci, Christel Galvani, Andrea Urbani

    Several genes are involved in sport performance, especially in injuries incidence. The aim of this study was to investigate the association of ACE, ACTN3, COL1A1, and MCT1 genotypes and injuries in rugby players in order to find a genotype/phenotype correlation and provide useful information improving athletic performance. One-hundred male professional and semiprofessional rugby players were selected. Analysis was performed genotyping the genes ACE, ACTN3, COL1A1, and MCT1 as candidate gene of interest involved in athletic performance. A control group of non-athletic Italian male participants was analyzed to compare the results. We found statistical significance of MCT1 rs1049434 AA for total injuries (χ2 = 0.115; p = 0.003) and bone injuries (χ2 = 0.603; p = 0.007) in the rugby athlete population. No statistical significance was found between injury incidence and ACE, ACTN3, COL1A1 genotypes. The MCT1 AA genotype is associated with the incidence of total and bone injuries in the rugby player population. Although environmental factors such as lifestyle, diet, training, and stress can influence athletic performance, our data demonstrated the importance of genetic study in sport aimed at developing personalized training and achieving the best possible athletic excellence.


  • Open Access

    The Relationship between ACE, ACTN3 and MCT1 Genetic Polymorphisms and Athletic Performance in Elite Rugby Union Players: A Preliminary Study

    by Massimo Pasqualetti, Maria Elisabetta Onori, Giulia Canu, Giacomo Moretti, Angelo Minucci, Silvia Baroni, Alvaro Mordente, Andrea Urbani, Christel Galvani

    Athletic performance is influenced by many factors such as the environment, diet, training and endurance or speed in physical effort and by genetic predisposition. Just a few studies have analyzed the impact of genotypes on physical performance in rugby. The aim of this study was to verify the modulation of genetic influence on rugby-specific physical performance. Twenty-seven elite rugby union players were involved in the study during the in-season phase. Molecular genotyping was performed for: angiotensin-converting enzyme (ACE rs4646994), alfa-actinin-3 (ACTN3 rs1815739) and monocarboxylate transporter 1 (MCT1 rs1049434) and their variants. Lean mass index (from skinfolds), lower-limb explosive power (countermovement jump), agility (505), speed (20 m), maximal aerobic power (Yo-yo intermittent recovery test level 1) and repeated sprint ability (12 × 20 m) were evaluated. In our rugby union players ACE and ACTN3 variants did not show any influence on athletic performance. MCT1 analysis showed that TT-variant players had the highest peak vertical power (p = 0.037) while the ones with the AA genotype were the fastest in both agility and sprint tests (p = 0.006 and p = 0.012, respectively). Considering the T-dominant model, the AA genotype remains the fastest in both tests (agility: p = 0.013, speed: p = 0.017). Only the MCT1 rs1049434 A allele seems to be advantageous for elite rugby union players, particularly when power and speed are required.


  • The role of biomarkers in drug-resistant trigeminal neuralgia: a prospective study in patients submitted to surgical treatment

    by Alessandro Rapisarda, Silvia Baroni, Vanessa Gentili, Giacomo Moretti, Benedetta Burattini, Francesca Sarlo, Alessandro Olivi, Andrea Urbani, Nicola Montano

    Background Molecular mechanisms underlying trigeminal neuralgia (TN) have been poorly understood. Recently, different biomarkers have been studied in several chronic neuropathic diseases or in neuronal damage, but their role in TN has not yet been investigated. Here, we firstly analyzed the serum levels of the neuron-specific enolase (NSE) (as an index of neuronal tissue damage) in TN patients submitted to surgical treatment. Different cytokines and interleukins related to inflammation were also studied. Methods Blood samples from 40 patients were prospectively collected preoperatively and after the surgical procedure, namely microvascular decompression (MVD) and percutaneous balloon compression (PBC). Serum levels of uric acid, NSE, ferritin, CRP, IL-2R, and IL-6 were studied. The acute pain relief (APR) and the pre- and postoperative BNI were used to evaluate the clinical outcome. Results Overall, we obtained an APR in 87.5% of patients and a significant reduction of BNI after surgery (p < 0.0001). We observed a significant reduction of postoperative NSE values in the group of patients undergoing MVD (p = 0.0055) and a significant increase of postoperative NSE values in patients undergoing PBC (p < 0.05). Furthermore, in the group of patients undergoing MVD, we found a significant postoperative increase of CRP (p < 0.0001), ferritin (p = 0.001), and IL-6 (p = 0.01) values. The only patient who did not respond to MVD had NSE levels unchanged. Conclusion Our results suggest the hypothesis that TN would be related to the neural damage instead of the systemic inflammatory status and indicate NSE as a possible biomarker of response in patients submitted to MVD.


  • Analytical performance evaluation of the new sST2 turbidimetric assay implemented in laboratory automation systems

    by Francesca Sarlo, Cristina De Luca, Giacomo Moretti, Andrea Urbani, Silvia Baroni

    Article Analytical performance evaluation of the new sST2 turbidimetric assay implemented in laboratory automation systems was published on October 18, 2021 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 0, issue 0).